Novo Nordisk A/S held its Annual General Meeting on March 26, 2026 approved election of Helena Saxon, Jan van de Winkel, and Ramona Sequeira as members of the Board of Directors. After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees. The Board of Directors, including its committees, is now composed as follows: Lars Rebien Sørensen (chair of the Board of Directors, chair of the Chair Committee, and chair of the People & Governance Committee); Cees de Jong (vice chair of the Board of Directors, chair of the Remuneration Committee, member of the Chair Committee, and member of the Audit Committee); Stephan Engels (chair of the Audit Committee and member of the People & Governance Committee); Britt Meelby Jensen (member of the Remuneration Committee and member of the Research & Development Committee); Kasim Kutay (member of the Research & Development Committee); Helena Saxon (member of the People & Governance Committee and member of the Audit Committee); Jan van de Winkel (chair of the Research & Development Committee); Ramona Sequeira (member of the Remuneration Committee and member of the Research & Development Committee); Semsi Kilic Madsen (employee-elected Board member and member of the People & Governance Committee); Mette Bøjer Jensen (employee-elected Board member and member of the Audit Committee); Désirée Jantzen Asgreen (employee-elected Board member and member of the Research & Development Committee); Elisabeth Dahl Christensen (employee-elected Board member and member of the Remuneration Committee).